remdesivir
Productby Gilead Sciences
Heard in 2 episodes across 2 shows since Sep 2026
An antiviral medication developed by Gilead Sciences and authorized or approved in multiple jurisdictions for treating certain patients with COVID-19.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 1 |
| Oct 2026 | 0 |
| Nov 2026 | 1 |
Email alert
Email me when remdesivir comes up on a podcast
One email a week at most, with the new episodes that mention remdesivir. Free, no account needed, unsubscribe in one click.
What experts have said about remdesivir
2 statements · 2 negative
Remdesivir was ineffective and toxic to the kidneys and liver.
“they say, listen, we were right. Remdesivir still doesn't work. It's got kidney and liver toxicities. It should never have been used.”
Open the episode · #2576 - Dr. Peter McCulloughListen at 1:09:47
Remdesivir was ineffective and toxic to the kidneys and liver.
“Remdesivir still doesn't work. It's got kidney and liver toxicities. It should never have been used.”
Open the episode · #2576 - Dr. Peter McCulloughListen at 1:09:48
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring remdesivir, newest first
